1

1

SPYROS A. POURNARAS 2

MEDICAL MICROBIOLOGIST - BIOPATHOLOGIST 3

PROFESSOR OF CLINICAL MICROBIOLOGY 4

5

6

7

8

DEPARTMENT of MICROBIOLOGY 9

MEDICAL SCHOOL, 10

NATIONAL & KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE 11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Athens, September 2016 29

30

2

PERSONAL INFORMATION 31

Name: POURNARAS, Spyros 32

Date of Birth: 4 November 1969 33

Marital Status: Married, three children 34

1993: MD, Medical School, Aristotelian University of Thessaloniki (A.U.T.) 35

1994-1998: Registrar in Medical Microbiology-Biopathology, Department of Microbiology, 36

AHEPA University Hospital, Medical School, A.U.T. 37

1999: Medical Specialty in Medical Microbiology-Biopathology 38

2000: PhD, Medical School, A.U.T. 39

2001: Lecturer, Department of Microbiology, Faculty of Medicine, School of Health Sciences, 40

University of Thessaly 41

2007: Assistant Professor of Microbiology, Department of Microbiology, Faculty of Medicine, 42

School of Health Sciences, University of Thessaly 43

2009-2013: Head, Department of Clinical Chemistry, Faculty of Medicine, School of Health 44

Sciences, University of Thessaly 45

2013- : Associate Professor of Microbiology, Department of Microbiology, School of Medicine, 46

University of Athens 47

2014-: Attending Guest Professor, Laboratory of Medical Microbiology and Infection 48

Prevention, University Medical Centre of Groningen, Groningen, The Netherlands 49

2016-: Professor of Microbiology, Department of Microbiology, School of Medicine, University 50

of Athens 51

52

3

TEACHING EXPERIENCE AND ACTIVITIES 53

1995-1999: Educational activities for undergraduate medical students of the Aristotle 54

University of Thessaloniki in the Laboratory of Microbiology of AHEPA Univ. Hospital 55

1998-2001: Educational activities in Molecular Microbiological methods for residents in Midical 56

Biopathology in Hippokration General Hospital of Thessaloniki 57

2002-2012: Independent educational activities in Medical Microbiology for undergraduate 58

medical students of the University of Thessaly 59

2011-2013: Educational activities in Medical Microbiology as Associate Professor Elect for 60

undergraduate medical and dental students of the University of Athens 61

2008-2012: Professor in charge for the course ‘‘Applications of Molecular Microbiology’’ for 62

undergraduate students of the Medical School of the University of Thessaly 63

2009-2012: Scientific Coordinator of Postgraduate Courses and Workshops of the Laboratory of 64

Clinical Chemistry at the Medical School of the University of Thessaly. 65

2013-: Regular educational activities in Medical Microbiology as Associate Professor for 66

undergraduate medical and dental students of the University of Athens 67

2014-: Practical exercises for undergraduate medical and dental students of the University of 68

Athens 69

2004-2008 and 2010-2014: Educational activities in the course ‘Microbiology-Mycology’ of the 70

Inter-Faculty Postgraduate Program of University of Athens: ‘‘Clinical Biochemistry – Molecular 71

Diagnostics’’ 72

2006-2007: Scientific coordinator for the course of Microbiology for the Postgraduate Program 73

of University of Thessaly ‘Molecular Medicine’ 74

2006-2008 and 2009-2014: Teaching activities in Microbiology, Scientific coordinator of the 75

course ‘‘General Microbiology’’ and member of the Scientific Committee for the Postgraduate 76

Program of University of Thessaly ‘Applied Public Health and Environmental Hygiene’ 77

2012: Educational activities for residents in Medical Biopathology within the regular 78

educational program of the Hellenic Microbiological Society 79

4

2013-: Educational activities in the course ‘Pharmaceutical Microbiology’ for the Postgraduate 80

Program of University of Athens: ‘‘Industrial Pharmacy and Pharmaceutical Analysis – Quality 81

Control” 82

2014-: Attending Guest Professor at Laboratory of Medical Microbiology and Infection 83

Prevention, University Medical Centre of Groningen, Groningen, with research and teaching 84

activities, and further scientific cooperation (preparations of grant proposals etc.) 85

86

PhD THESES 87

Supervisor in 14 PhD theses, 8 of which were completed with degree “Excellent” 88

Member of the 3-membered consulting committee in further 14 PhD theses 89

Member of the 7-membered examination Committee in further 15 PhD theses 90

91

CLINICAL WORK 92

Dec 1994 – Dec 1998: Clinical laboratory activities as Registrar in Medical Microbiology-93

Biopathology, Department of Microbiology, AHEPA University Hospital 94

Feb 1999 – March 2001: Research Associate in the Department of Microbiology, AHEPA 95

University Hospital 96

Jan 2000 – Nov 2001: Research Associate in the Department of Microbiology, University 97

Hospital of Larissa, Medical School, University of Thessaly 98

Apr 2002 – Jan 2013: Clinical laboratory activities in the laboratories of Molecular Microbiology, 99

Serology, Bacteriology and Clinical Chemistry, University Hospital of Larissa, Medical School, 100

University of Thessaly 101

2004 – 2013: Member of the Infection Control Committee, University Hospital of Larissa, 102

Medical School, University of Thessaly 103

Aug 2006 – Mar 2009: Head, Laboratory of Bacteriology, University Hospital of Larissa, Medical 104

School, University of Thessaly 105

Feb 2008 - Mar2009: Head, Laboratory of Clinical Chemistry, University Hospital of Larissa, 106

Medical School, University of Thessaly 107

5

Mar 2009 – Jan 2013: Director, Laboratory of Clinical Chemistry, University Hospital of Larissa, 108

Medical School, University of Thessaly 109

2014 - : Laboratory activities as Research Associate in the Laboratory of Hygiene and 110

Epidemiology, Medical School, University of Thessaly 111

2014 - : Laboratory activities in the Laboratory of Microbiology, Aretaieio University Hospital, 112

Medical School, University of Athens 113

114

ORGANISATIONAL-ADMINISTRATIVE ACTIVITIES 115

Director, Department of Clinical Chemistry, Faculty of Medicine, School of Health Sciences, 116

University of Thessaly (2009-2013) 117

Delegate (Representative) of the Clinical Laboratory Sector in the Educational Committee 118

of the Medical School of the University of Thessaly (2009-2011) 119

Delegate (Representative) of the Clinical Laboratory division in the General Assembly of the 120

Medical School of the University of Thessaly (2006-2007, 2008-2009, 2010-2011) 121

Member of the Committee of Greece CDC (KEELPNO) for antibiotic resistance (2009-2010) 122

Member of the 3-membered Committees of Greece CDC (KEELPNO) for surveillance of the 123

activities for containment of carbapenem resistance (2011) 124

Member of the Organizing Committee of the 5th International Meeting of the 125

European Laboratory Working Group on Diphtheria (1998) 126

Member of the Organizing Committee of the Laboratory Diagnosis of Diphtheria Workshop 127

(1999) 128

Member of the Scientific Committee and Local Organizer of the “10th International 129

Symposium on the Biology of Acinetobacter”, Athens, 3-5 June 2015 130

131

PARTICIPATION IN INTERNATIONAL FUNDED RESEARCH PROGRAMS 132

“DGXII Biomed 2, Microbiological Surveillance of Diphtheria in Europe” (as member of the 133

European Study Group for Diphtheria) 134

COST Action ΒM0701 ATENS (member of WG1 and Management Committee) 135

6

Research program: «The occurrence and survival of enteropathogenic Escherichia coli 136

O157:H7 in milk and milk products in Greece and Slovakia» 137

138

RESEARCH GRANTS 139

ESCMID Research Grant, 20,000 Euros, for clinical and molecular investigation of linezolid 140

resistance (2008) (led to the publication No. 115) 141

Research program funded through the Research Committee of the University of Thessaly, 142

entitled Biofilm and Infections”; 109,000 Euros (led to the publications No. 81, 111) 143

International Research program funded from Pfizer, entitled “In vivo investigation of the 144

activity of tigecycline, alone and in combination with colistin, meropenem, rifampicin or 145

gentamicin against KPC-producing Enterobacteriaceae clinical isolates in a murine thigh 146

model”; 40,000 Euros (led to the publication No. 130) 147

Research program funded through the Research Committee of the University of Thessaly, 148

entitled “Biochemical and molecular investigation of carbapenem-hydrolyzing enzymes”, 149

12,000 Euros 150

Research program funded through the Research Committee of the University of Thessaly, 151

entitled "Study of the membrane proteins of Gram (-) bacteria", 24,000 Euros 152

Research program funded through the Research Committee of the University of Thessaly, 153

entitled "Study of the lipid profile of the membrane of of Gram (-) bacteria", 8,000 Euros 154

International Clinical Study funded from PSI CRO AG for the treatment of acute urinary 155

infections using experimental antibiotics 156

157

SCIENTIFIC ACTIVITIES 158

CONTRIBUTION TO TEXTBOOKS, BOOKS, E-BOOKS 159

Contribution to the Textbook “Clinical Microbiology”, J. Douboyas, A. Tsakris”, University 160

Studio Press, 1st Edition 2000 & 2nd Edition 2002 161

A. N. Maniatis, E. Petinaki, S. Pournaras. Chapter: “Molecular epidemiology and resistance 162

mechanisms of enterococci to oxazolidinones and streptogramins”, in “Drug Resistance of 163

7

Enterococci: Epidemiology and Molecular Mechanisms”, 2006, Bentham Science Publishers 164

(Editor N. Kobayashi) 165

S. Pournaras. Chapter: “Control of Multidrug Resistance”, in the E-Book “Multi-drug 166

resistance: a global concern”, 2010, Bentham Science Publishers (Editor A. Khan) 167

168

INTERNATIONAL COLLABORATIONS WITH RESEARCH TEAMS 169

Professor Neil Woodford, Health Protection Agency, Colindale, London 170

Professor Androulla Efstratiou, Respiratory and Systemic Infections Laboratory, Health 171

Protection Agency, Colindale, Λονδίνο 172

Professor Leonard Amaral, Institute of Hygiene & Tropical Medicine, Universidade Nova de 173

Lisboa, Portugal 174

Professor Herman Goossens, University of Antwerp, Belgium 175

Professor Alexander Friedrich, University of Groningen, the Netherlands 176

Professor Hajo Grundmann, University of Groningen, the Netherlands 177

Professor Bhanu Sinha, University of Groningen, the Netherlands 178

Associate Professor Raffaele Zarrilli, University of Naples, Italy 179

Professor Emmanuelle De, University of Rouen, France 180

Professor Thomas J Walsh, Cornell University, USA 181

Professor Harald Seifert, University of Cologne, Germany 182

Professor Gian Maria Rossolini, University of Siena, Italy 183

Associate Professor Christian Giske, ECDC, Sweden 184

185

PUBLICATIONS IN PEER-REVIEWED MEDICAL JOURNALS: 157 186

Sum Impact Factor (IF): 640 187

Mean Impact Factor (IF): 4.1 188

H-Index: 31

Citations: 3,300 (SCOPUS)

8

EDITORIAL BOARD MEMBER IN PEER-REVIEWED MEDICAL JOURNALS: 189

1. Journal of Antimicrobial Chemotherapy (IF 5,439), since 2008 190

2. BMC Microbiology (IF 2,976), since 2014 191

3. Chemotherapy Research and Practice, since 2009 192

4. Recent Patents on Anti-Infective Drug Discovery, since 2013 193

5. Data Set Papers in Medicine, since 2012 194

195

REVIEWER IN INTERNATIONAL AND NATIONAL GRANT ORGANIZATIONS 196

1. National Science Centre, Poland 197

2. Research Foundation Flanders, Belgium (FWO) 198

3. The Netherlands Organisation For Health Research And Development (ZONMW) 199

4. Austrian Science Fund (FWF) 200

5. ESCMID Research Grant Reviewer 2015 (ESCMID Database of Trusted Reviewers) 201

6. Research granting program "Karatheodori", University of Patras, Greece 202

7. Research Committee Grants, University of Crete, Greece 203

204

REVIEWER IN 56 PEER-REVIEWED INTERNATIONAL MEDICAL JOURNALS 205

1) Journal of Antimicrobial Chemotherapy 206

2) Journal of Medical Microbiology 207

3) BMC Microbiology 208

4) BMC Infectious Diseases 209

5) Emerging Infectious Diseases 210

6) Journal of Medical Virology 211

7) Clinical Microbiology and Infection 212

8) Plos ONE 213

9) Clinical Infectious Diseases 214

10) Clinical Chemistry 215

11) Antimicrobial Agents and Chemotherapy 216

9

12) Infection Control and Hospital Epidemiology 217

13) Future Microbiology 218

14) Applied and Environmental Microbiology 219

15) Journal of Bacteriology 220

16) Journal of Clinical Microbiology 221

17) BMC Clinical Pathology 222

18) Microbiology 223

19) Journal of Infection 224

20) International Journal of Microbiology 225

21) Microbial Drug Resistance 226

22) Diagnostic Microbiology and Infectious Diseases 227

23) FEMS Microbiology Letters 228

24) International Journal of Antimicrobial Agents 229

25) European Journal of Clinical Microbiology and Infectious Diseases 230

26) BMC Research Notes 231

27) Scandinavian Journal of Infectious Diseases 232

28) Annals of Clinical Microbiology and Antimicrobials 233

29) PhotoChemistry and Photobiology 234

30) BMC Complementary and Alternative Medicine 235

31) Pediatric Blood Cancer 236

32) Folia Microbiologica 237

33) Medical Principles and Practice 238

34) Journal of Infection and Public Health 239

35) Asian Journal of Medical Sciences 240

36) Expert Opinion in Investigating Drugs 241

37) Open Microbiology Journal 242

38) Zoonoses and Public Health 243

39) Archives of Medical Research 244

40) International Journal of Infectious Diseases 245

10

41) International Journal of Modern Biological Research 246

42) Current Drug Targets 247

43) Recent Patents on Anti-Infective Drug Discovery 248

44) Global Research Journal of Microbiology 249

45) Journal of Water and Health 250

46) Respiratory Care 251

47) Journal of Infection and Chemotherapy 252

48) Journal of Global Antimicrobial Resistance 253

49) African Journal of Biotechnology 254

50) SAR and QSAR in Environmental Research 255

51) Indian Journal of Cancer 256

52) Photomedicine and Laser Surgery 257

53) Expert Review of Anti-Infective Therapy 258

54) Annals of Microbiology 259

55) Annals of Pharmacotherapy 260

56) Journal of Clinical Laboratory Analysis 261

262

263

11

LIST OF PUBLICATIONS IN PEER-REVIEWED MEDICAL JOURNALS 264

1. TSAKRIS A, POURNARAS S, DOUBOYAS J. Changes in antimicrobial resistance of enterococci 265

isolated in Greece. Journal of Antimicrobial Chemotherapy 1997; 40: 735-737. 266

2. TSAKRIS A, WOODFORD N, POURNARAS S, KAUFMANN M, DOUBOYAS J. Apparent increased 267

prevalence of high-level aminoglycoside-resistant Enterococcus durans resulting from false 268

identification by a semiautomated software system. Journal of Clinical Microbiology 1998; 36: 269

1419-1421. 270

3. TSAKRIS A, POURNARAS S, HATHI D, DOUBOYAS J, EFSTRATIOU A. Outbreak of rare serotype 271

of group A streptococcus pharyngitis in a boarding college. Lancet 1999; 353: 1585-1586. 272

4. SKOURA L, EFSTRATIOU A, TSAKRIS A, POURNARAS S, GEORGE RC, DOUBOYAS J. Study on the 273

use of an enzyme-linked immunosorbent assay in determining human antibodies to diphtheria 274

toxin as compared with a reference toxin neutralization assay. Comparative Immunology, 275

Microbiology and Infectious Diseases 1999; 22: 181-186. 276

5. POURNARAS S, TSAKRIS A, MANDRAVELI K, FAITATZIDOU A, DOUBOYAS J, TOURKANTONIS A. 277

Reported needlestick and sharp injuries among health care workers in a Greek general hospital. 278

Occupational Medicine 1999; 49: 423-426. 279

6. POURNARAS S, TSAKRIS A, HADJICHRISTODOULOU C, SKOURA L, SOULIOU E, ANTONIADIS A, 280

DOUBOYAS J. Diphtheria immunity of Albanian and other eastern European immigrants in 281

Greece compared with the local population. The risk of reemergence in Greece. Infection 1999; 282

27: 361-364. 283

7. TSAKRIS A, POURNARAS S, WOODFORD N, PALEPOU MFI, BABINI GS, DOUBOYAS J, 284

LIVERMORE DM. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 285

carbapenemase in Greece. Journal of Clinical Microbiology 2000; 38: 1290-1292. 286

8. POLYZOU A, SOFIANOU D, POURNARAS S, TSAKRIS A. RAPD-fingerprinting of Serratia 287

marcescens after formaldeyde inactivation of DNAse activity. Letters in Applied Microbiology 288

2000; 30: 419-421. 289

9. TSAKRIS A, PANTAZI A, POURNARAS S, MANIATIS A, POLYZOU A, SOFIANOU D. Pseudo-290

outbreak of imipenem-resistant Acinetobacter baumannii resulting from false susceptibility 291

testing by a rapid automated system. Journal of Clinical Microbiology 2000; 38: 3505-3507. 292

10. POURNARAS S, TSAKRIS A, KAUFMANN ME, DOUBOYAS J, ANTONIADIS A. Outbreak of 293

infections in a Greek university hospital involving a single clone of high-level aminoglycoside-294

resistant Enterococcus faecalis. Infection Control and Hospital Epidemiology 2000; 21: 786-295

789. 296

11. POURNARAS S, TSAKRIS A, PALEPOU MFI, PAPA A, DOUBOYAS J, ANTONIADIS A, 297

WOODFORD N. Pheromone responses and high-level aminoglycoside resistance of conjugative 298

plasmids of Enterococcus faecalis from Greece. Journal of Antimicrobial Chemotherapy 2000; 299

46:1013-1016. 300

12. MAVROIDI A, TSAKRIS A, TZELEPI E, POURNARAS S, LOUKOVA V, TZOUVELEKIS LS. 301

Carbapenem-hydrolysing VIM-2 metallo--lactamase in Pseudomonas aeruginosa from Greece. 302

Journal of Antimicrobial Chemotherapy 2000; 46: 1041-1043. 303

13. POURNARAS S, EFSTRATIOU A, DOUBOYAS J, GEORGE RC, TSAKRIS A. Genetic relatedness of 304

group A streptococci of the newly designated serotype M90 causing a food-borne outbreak and 305

sporadic infections. Epidemiology and Infection 2000; 125: 299-301. 306

12

14. TSAKRIS A, POURNARAS S, MANIATIS AN, DOUBOYAS J, ANTONIADIS A. Increasing 307

prevalence of high-level gentamicin-resistance among enterococci isolated in Greece. 308

Chemotherapy 2001; 47: 86-89. 309

15. POURNARAS S, SLAVAKIS A, POLYZOU A, SOFIANOU D, MANIATIS AN, TSAKRIS A. 310

Nosocomial spread of an unusual methicillin-resistant Staphylococcus aureus clone that is 311

sensitive to all non--lactam antibiotics, including tobramycin. Journal of Clinical Microbiology 312

2001; 39: 779-781. 313

16. PETINAKI E, MIRIAGOU V, TZOUVELEKIS LS, POURNARAS S, HATZI F, KONTOS F, MANIATI M, 314

MANIATIS AN AND THE BACTERIAL RESISTANCE STUDY GROUP OF THESSALY. Methicillin-315

resistant Staphylococcus aureus in the hospitals of central Greece. International Journal of 316

Antimicrobial Agents 2001; 18: 61-65. 317

17. POLYZOU A, SLAVAKIS A, POURNARAS S, MANIATIS AN, SOFIANOU D, TSAKRIS A. 318

Predominance of a methicillin-resistant Staphylococcus aureus clone susceptible to 319

erythromycin and several other non--lactam antibiotics in a Greek hospital. Journal of 320

Antimicrobial Chemotherapy 2001; 48: 231-234. 321

18. MANIATIS AN, POURNARAS S, KANELLOPOULOU M, KONTOS F, DIMITROULIA E, 322

PAPAFRANGAS E, TSAKRIS A. Dissemination of clonally unrelated erythromycin- and 323

glycopeptide-resistant Enterococcus faecium isolates in a tertiary Greek hospital. Journal of 324

Clinical Microbiology 2001; 39: 4571-4574. 325

19. TSAKRIS A, HASSAPOPOULOU H, SKOURA L, POURNARAS S, DOUBOYAS J. Leg ulcer due to 326

Pseudomonas luteola in a patient with sickle cell disease. Diagnostic Microbiology and 327

Infectious Diseases 2002; 42:141-143. 328

20. KARTALI G, TZELEPI E, POURNARAS S, KONTOPOULOU C, KONTOS F, SOFIANOU D, MANIATIS 329

AN, TSAKRIS A. Outbreak of infections caused by Enterobacter cloacae producing the integron-330

associated -lactamase IBC-1 in a neonatal intensive care unit of a Greek hospital. 331

Antimicrobial Agents and Chemotherapy 2002; 46:1577-1580. 332

21. POURNARAS S, TSAKRIS A, MANIATI M, TZOUVELEKIS LS, MANIATIS AN. Novel variant 333

(blaVIM-4) of the metallo-β-lactamase gene blaVIM-1 in a clinical strain of Pseudomonas 334

aeruginosa. Antimicrobial Agents and Chemotherapy 2002; 46: 4026-4028. 335

22. MANIATIS AN, POURNARAS S, ORKOPOULOU S, TASSIOS PT, LEGAKIS NJ, AND THE 336

BACTERIAL RESISTANCE STUDY GROUP. Multi-resistant Acinetobacter baumannii isolates in 337

intensive care units in Greece. Clinical Microbiology and Infection 2003; 9: 547-553. 338

23. POURNARAS S, MANIATI M, PETINAKI E, TZOUVELEKIS LS, TSAKRIS A, LEGAKIS NJ, MANIATIS 339

AN. Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated 340

metallo-β-lactamase gene variants blaVIM-2 and blaVIM-4. Journal of Antimicrobial Chemotherapy 341

2003; 51: 1409-1414. 342

24. TSAKRIS A, TSIONI C, POURNARAS S, POLYZOS S, MANIATIS AN, SOFIANOU D. Spread of low-343

level carbapenem-resistant Acinetobacter baumannii clones in a tertiary care Greek hospital. 344

Journal of Antimicrobial Chemotherapy 2003; 52: 1046-1047. 345

25. POURNARAS S, MALAMOU-LADA H, MANIATI M, MYLONA-PETROPOULOU D, VAGIAKOU-346

VOUDRIS H, TSAKRIS A, MANIATIS AN. Persistence of a clone of glycopeptide-resistant 347

Enterococcus faecalis among patients in an intensive care unit of a Greek hospital. Journal of 348

Antimicrobial Chemotherapy 2004; 53: 109-112. 349

13

26. SOFIANOU D, AVGOUSTINAKIS M, DILOPOULOU A, POURNARAS S, TSIRAKIDIS G, TSAKRIS A. 350

Soft-tissue abscess involving Actinomyces odontolyticus and two Prevotella species in an 351

intravenous drug abuser. Comparative Immunology, Microbiology and Infectious Diseases 352

2004; 27: 75-79. 353

27. KANELLOPOULOU M, POURNARAS S, IGLEZOS H, PAPAFRANGAS E, MANIATIS AN. Persistent 354

colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans 355

clone. European Journal of Clinical Microbiology Infectious Diseases 2004; 23: 336-339. 356

28. POLYZOU A, POURNARAS S, DAFNI U, SOFIANOU D, CHRISTELI E, PATRINOS S, TSAKRIS A. 357

Seroepidemiology of Bordetella pertussis immune responses in a healthy population in Northern 358

Greece. Journal of Clinical Laboratory Analysis 2004; 18: 211-214. 359

29. POURNARAS S, IKONOMIDIS A, SOFIANOU D, TSAKRIS A, MANIATIS AN. CTX-M-type β-360

lactamases affect community Escherichia coli treatment, Greece. Emerging Infectious Diseases 361

2004; 10: 1163-1164. 362

30. SOFIANOU D, POURNARAS S, GIOSI M, POLYZOU A, MANIATIS AN, TSAKRIS A. Substantially 363

increased faecal carriage of vancomycin-resistant enterococci in a tertiary Greek hospital after a 364

four-year time interval. Journal of Antimicrobial Chemotherapy 2004; 54: 251-254. 365

31. POURNARAS S, IKONOMIDIS A, KRISTO I, TSAKRIS A, MANIATIS AN. CTX-M enzymes are the 366

most common extended-spectrum β-lactamases among Escherichia coli in a tertiary Greek 367

hospital. Journal of Antimicrobial Chemotherapy 2004; 54: 574-575. 368

32. POURNARAS S, IKONOMIDIS A, MARKOGIANNAKIS A, MANIATIS AN, TSAKRIS A. 369

Heteroresistance to carbapenems in Acinetobacter baumannii. Journal of Antimicrobial 370

Chemotherapy 2005; 55: 1055-1056. 371

33. IKONOMIDIS A, TOKATLIDOU D, KRISTO I, SOFIANOU D, TSAKRIS A, MANTZANA P, 372

POURNARAS S, MANIATIS AN. Outbreaks in distinct regions due to a single Klebsiella 373

pneumoniae clone carrying blaVIM-1 metallo-β-lactamase gene. Journal of Clinical Microbiology 374

2005; 43: 5344-5347. 375

34. POURNARAS S, MANIATI M, SPANAKIS N, IKONOMIDIS A, TASSIOS PT, TSAKRIS A, LEGAKIS 376

NJ, MANIATIS AN. Spread of efflux pump over-expressing, non-metallo--lactamase-producing, 377

meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with 378

blaVIM endemicity. Journal of Antimicrobial Chemotherapy 2005; 56: 761-764. 379

35. DAPONTE A, POURNARAS S, ZINZARAS E, KALLITSARIS A, LIALIOS G, MANIATIS AN, 380

MESSINIS IE. The value of a single combined measurement of VEGF, glycodelin, progesterone, 381

PAPP-A, HPL and LIF for the differentiation between ectopic and abnormal intrauterine 382

pregnancy. Human Reproduction 2005; 20: 3163-3166. 383

36. POURNARAS S, IKONOMIDIS A, TZOUVELEKIS LS, SOFIANOU D, SPANAKIS N, MANIATIS AN, 384

LEGAKIS NJ, TSAKRIS A. VIM-12, a novel plasmid-mediated metallo-β-lactamase from Klebsiella 385

pneumgniae that resembles a VIM-1/2 hybrid. Antimicrobial Agents and Chemotherapy 2005; 386

49: 5153-5156. 387

37. STEFOS A, GEORGIADOU SP, GIOTI C, LOUKOPOULOS A, IOANNOU M, POURNARAS S, 388

DALEKOS GN. Leptospirosis and pancytopenia: two case reports and review of the literature. 389

Journal of Infection 2005; 51: e277-280. 390

38. KARAPAVLIDOU P, SOFIANOU D, MANOLIS EN, POURNARAS S, TSAKRIS A. CTX-M-1 391

extended-spectrum-β-lactamase-producing Proteus mirabils in Greece. Microbial Drug 392

Resistance 2005; 11: 351-354. 393

14

39. SOFIANOU D, MARKOGIANNAKIS A, METZIDIE E, POURNARAS S, TSAKRIS A. VIM-2 metallo-394

β-lactamase in Achromobacter xylosoxidans in Europe. European Journal of Clinical 395

Microbiology and Infectious Diseases 2005; 24: 854-855. 396

40. METZIDIE E, MANOLIS EN, POURNARAS S, SOFIANOU D, TSAKRIS A. Spread of an unusual 397

penicillin- and imipenem-resistant but ampicillin-susceptible phenotype among Enterococcus 398

faecalis clinical isolates. Journal of Antimicrobial Chemotherapy 2006; 57: 158-160. 399

41. POURNARAS S, MARKOGIANNAKIS A, IKONOMIDIS A, KONDYLI L, BETHIMOUTI K, MANIATIS 400

AN, LEGAKIS NJ, TSAKRIS A. Outbreak of multiple clones of imipenem-resistant Acinetobacter 401

baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. Journal of 402

Antimicrobial Chemotherapy 2006; 57: 557-561. 403

42. POURNARAS S, TSAKRIS A, IKONOMIDIS A, MARKOGIANNAKIS A, KRISTO I, MANIATIS AN. 404

Detection of a novel variant blaCTX-M-3 extended spectrum β-lactamase gene in a community-405

acquired Escherichia coli isolate. Scandinavian Journal of Infectious Diseases 2006; 38: 213-406

216. 407

43. DAPONTE A, POURNARAS S, HADJICHRISTODOULOU C, LIALIOS G, KALLITSARIS A, MANIATIS 408

AN, MESSINIS IE. Novel serum inflammatory markers in patients with adnexal mass who were 409

operated on because of ovarian torsion. Fertility and Sterility 2006; 85: 1469-1472. 410

44. TSAKRIS A, IKONOMIDIS A, POURNARAS S, TZOUVELEKIS LS, SOFIANOU D, LEGAKIS NJ, 411

MANIATIS AN. VIM-1 Metallo-β-lactamase in Acinetobacter baumannii. Emerging Infectious 412

Diseases 2006; 12: 981-983. 413

45. DAPONTE A, POURNARAS S, MADEMTZIS I, HADJICHRISTODOULOU C, KOSTOPOULOU E, 414

MANIATIS AN, MESSINIS IE. Evaluation of high-risk human papillomavirus types PCR detection in 415

paired urine and cervical samples of women with abnormal cytology. Journal of Clinical 416

Virology 2006; 36: 189-193. 417

46. IKONOMIDIS A, POURNARAS S, MANIATIS AN, LEGAKIS NJ, TSAKRIS A. Discordance of 418

meropenem versus imipenem activity aganist Acinetobacter baumannii. International Journal 419

of Antimicrobial Agents 2006; 28: 376-377. 420

47. DAPONTE A, POURNARAS S, MADEMTZIS I, HADJICHRISTODOULOU C, KOSTOPOULOU E, 421

MANIATIS AN, MESSINIS IE. Evaluation of HPV 16 PCR detection in self- compared with clinician-422

collected samples in women referred for colposcopy. Gynecological Oncology 2006; 103: 463-423

466. 424

48. TSAKRIS A, IKONOMIDIS A, POURNARAS S, SPANAKIS N, MARKOGIANNAKIS A. Carriage of 425

OXA-58 but not of OXA-51 correlates with carbapenem resistance in Acinetobacter baumannii. 426

Journal of Antimicrobial Chemotherapy 2006; 58: 1097-1099. 427

49. POURNARAS S, IKONOMIDIS A, MARKOGIANNAKIS A, SPANAKIS N, MANIATIS AN, TSAKRIS A. 428

Characterisation of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to 429

carbapenems. Journal of Medical Microbiology 2007; 56: 66-70. 430

50. TSAKRIS A, IKONOMIDIS A, SPANAKIS N, POURNARAS S, BETHIMOUTI K. Identification of a 431

novel blaOXA-51 variant, blaOXA-92, from a clinical isolate of Acinetobacter baumannii. Clinical 432

Microbiology and Infection 2007; 13: 348-349. 433

51. TSAKRIS A, IKONOMIDIS A, SPANAKIS N, POULOU A, POURNARAS S. Characterization of 434

In3Mor, a new integron carrying VIM-1 metallo-beta-lactamase and sat1 gene, from 435

Morganella morganii. Journal of Antimicrobial Chemotherapy 2007; 59: 739-741. 436

52. IKONOMIDIS A, POURNARAS S, MARKOGIANNAKIS A, MANIATIS AN, MANOLIS EN, TSAKRIS 437

15

A. Low genetic diversity of the intrinsic OXA-51-like class D carbapenemases among 438

Acinetobacter baumannii clinical isolates in Greece. Epidemiology and Infection 2006; 135: 877-439

881. 440

53. TSAKRIS A, IKONOMIDIS A, POULOU A, SPANAKIS N, POURNARAS S, MARKOU F. 441

Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-442

lactamase. Journal of Antimicrobial Chemotherapy 2007; 60: 136-139. 443

54. MANIATI M, IKONOMIDIS A, MANTZANA P, DAPONTE A, MANIATIS AN, POURNARAS S. A 444

highly carbapenem resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b 445

integron over-expresses two efflux pumps and lacks OprD”. Journal of Antimicrobial 446

Chemotherapy 2007; 60: 132-135. 447

55. IKONOMIDIS A, LABROU M, AFKOU Z, SOFIANOU D, MANIATIS AN, TSAKRIS A, POURNARAS 448

S. First οccurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid 449

metallo-β-lactamase VIM-12. Antimicrobial Agents and Chemotherapy 2007; 51: 3038-3039. 450

56. MELETIADIS J, ANTACHOPOULOS C, STERGIOPOULOU T, POURNARAS S, ROILIDES E, WALSH 451

TJ. Differential fungicidal activity of amphotericin B and voriconazole against Aspergillus species 452

determined by microbroth methodology. Antimicrobial Agents and Chemotherapy 2007; 51: 453

3329-3337. 454

57. KONSTANTINIDIS A, MINAS A, POURNARAS S, KANSOUZIDOU A, PAPASTERGIOU P, 455

MANIATIS A, STATHAKIS N, HADJICHRISTODOULOU C. Evaluation and comparison of 456

fluorescence polarization assay with three of the currently used serological tests in diagnosis of 457

human brucellosis. European Journal of Clinical Microbiology and Infectious Diseases 2007; 26: 458

715-721. 459

58. KONTOU M, POURNARAS S, KRISTO I, IKONOMIDIS A, MANIATIS AN, STATHOPOULOS C. 460

Molecular cloning and biochemical characterization of VIM-12, a novel hybrid VIM-1/VIM-2 461

metallo-beta-lactamase from a Klebsiella pneumoniae clinical isolate, reveals atypical substrate 462

specificity. Biochemistry 2007; 46: 13170-13178. 463

59. IKONOMIDIS A, SPANAKIS N, POULOU A, POURNARAS S, MARKOU F, TSAKRIS A. Emergence 464

of carbapenem-resistant Enterobacter cloacae carrying VIM-4 metallo-β-lactamase and SHV-2a 465

extended-σpectrum β-lactamase in a congugative plasmid. Microbial Drug Resistance 2007; 13: 466

221-226. 467

60. IKONOMIDIS A, NTOKOU E, MANIATIS AN, TSAKRIS A, POURNARAS S. Hidden VIM-1 metallo-468

beta-lactamase phenotypes among Acinetobacter baumannii clinical isolates. Journal of Clinical 469

Microbiology 2008; 46: 346-349. 470

61. IKONOMIDIS A, TSAKRIS A, KANTZANOU M, SPANAKIS N, MANIATIS AN, POURNARAS S. 471

Efflux systems overexpression and decreased OprD contribute to the carbapenem 472

heterogeneous growth in Pseudomonas aeruginosa. FEMS Microbiology Letters 2008; 279: 36-473

39. 474

62. TOKATLIDOU D, TSIVITANIDOU M, POURNARAS S, IKONOMIDIS A, TSAKRIS A, SOFIANOU D. 475

Outbreak caused by a multidrug-resistant Klebsiella pneumoniae clone carrying blaVIM-12 in a 476

University Hospital. Journal of Clinical Microbiology 2008; 46: 1005-1008. 477

63. POURNARAS S, IKONOMIDIS A, NEOU E, KANTZANOU M, MANIATIS AN, TSAKRIS A. 478

Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, 479

successfully treated by piperacillin/tazobactam. Journal of Antimicrobial Chemotherapy 2008; 480

61: 757-758. 481

16

64. MARKOGIANNAKIS A, FILDISIS G, TSIPLAKOU S, IKONOMIDIS A, KOUTSOUKOU A, 482

POURNARAS S, MANOLIS EN, BALTOPOULOS G, TSAKRIS A. Cross-transmission of multidrug-483

resistant Acinetobacter baumannii clonal strains causing episodes of sepsis in a trauma 484

intensive care unit. Infection Control and Hospital Epidemiology 2008; 29: 410-417. 485

65. TSAKRIS A, IKONOMIDIS A, POULOU A, SPANAKIS N, VRIZAS D, DIOMIDOUS M, POURNARAS 486

S, MARKOU F. Clusters of imipenem-resistant Acinetobacter baumannii clones producing 487

different carbapenemases in an intensive care unit. Clinical Microbiology and Infection 2008; 488

14: 588-594. 489

66. DAPONTE A, TSEZOU A, OIKONOMOU P, HADJICHRISTODOULOU C, MANIATIS A, 490

POURNARAS S, MESSINIS IE. Use of real-time PCR to detect human papillomavirus-16 viral loads 491

in vaginal and urine self-sampled specimens. Clinical Microbiology and Infection 2008; 14: 619-492

621. 493

67. VASILAKI O, NTOKOU E, IKONOMIDIS A, SOFIANOU D, FRANTZIDOU F, ALEXIOU-DANIEL S, 494

MANIATIS AN, POURNARAS S. Emergence of the plasmid-mediated quinolone resistance gene 495

qnrS1 in Escherichia coli genotypes in Greece. Antimicrobial Agents and Chemotherapy 2008; 496

52: 2996-2997. 497

68. IKONOMIDIS A, TSAKRIS A, KANELLOPOULOU M, MANIATIS AN, POURNARAS S. Effect of the 498

proton motive force inhibitor carbonyl cyanide-m-chlorophenylhydrazone (CCCP) on 499

Pseudomonas aeruginosa biofilm development. Letters in Applied Microbiology 2008; 47: 298-500

302. 501

69. IKONOMIDIS A, MICHAIL G, VASDEKI A, LABROU M, KARAVASILIS V, STATHOPOULOS C, 502

MANIATIS AN, POURNARAS S. In vitro and in vivo evaluations of oxacillin efficiency on mecA-503

positive oxacillin-susceptible Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 504

2008; 52: 3905-3908. 505

70. TSAKRIS A, KRISTO I, POULOU A, MARKOU F, IKONOMIDIS A, POURNARAS S. First occurrence 506

of KPC-2-possessing Klebsiella pneumoniae in a Greek hospital and recommendation for 507

detection with boronic acid disc tests. Journal of Antimicrobial Chemotherapy 2008; 62: 1257-508

1260. 509

71. TSAKRIS A, KRISTO I, POULOU A, THEMELI-DIGALAKI K, IKONOMIDIS A, PETROPOULOU D, 510

POURNARAS S, SOFIANOU D. Evaluation of boronic acid disk tests for differentiating KPC-511

possessing Klebsiella pneumoniae isolates in the clinical laboratory. Journal of Clinical 512

Microbiology 2009: 47: 362-367. 513

72. CHALVATZAS N, DAFOPOULOS K, KOSMAS G, KALLITSARIS A, POURNARAS S, MESSINIS IE. 514

Effect of ovarian hormones on serum adiponectin and resistin concentrations. Fertility and 515

Sterility 2009; 91: 1189-1194. 516

73. POURNARAS S, IOSIFIDIS E, ROILIDES E. Advances in antibacterial therapy against emerging 517

bacterial pathogens. Seminars in Hematology 2009; 46: 198-211. 518

74. POURNARAS S, PROTONOTARIOU E, VOULGARI E, KRISTO I, DIMITROULIA E, VITTI D, 519

TSALIDOU M, MANIATIS AN, TSAKRIS A, SOFIANOU D. Clonal spread of KPC-2 carbapenemase-520

producing Klebsiella pneumoniae strains in Greece. Journal of Antimicrobial Chemotherapy 521

2009; 64: 348-352. 522

75. DAFOPOULOS K, SOURLAS D, KALLITSARIS A, POURNARAS S, MESSINIS IE. Blood ghrelin, 523

resistin and adiponectin concentrations during the normal menstrual cycle. Fertility and Sterility 524

2009; 92: 1389-1394. 525

17

76. DAFOPOULOS K, VENETIS C, POURNARAS S, KALLITSARIS A, MESSINIS IE. Ovarian control of 526

pituitary sensitivity of luteinizing hormone secretion to gonadotropin-releasing hormone in 527

women with the polycystic ovary syndrome. Fertility and Sterility 2009; 92: 1378-1380. 528

77. TSAKRIS A, POULOU A, THEMELI-DIGALAKI K, VOULGARI E, PITTARAS T, SOFIANOU D, 529

POURNARAS S, PETROPOULOU D. Use of boronic acid disk tests to detect extended- spectrum 530

beta-lactamases in clinical isolates of KPC carbapenemase-possessing enterobacteriaceae. 531

Journal of Clinical Microbiology 2009; 47: 3420-3426. 532

78. TSAKRIS A, POULOU A, KRISTO I, PITTARAS T, SPANAKIS N, POURNARAS S, MARKOU F. Large 533

dissemination of VIM-2-metallo-beta-lactamase-producing pseudomonas aeruginosa strains 534

causing health care-associated community-onset infections. Journal of Clinical Microbiology 535

2009; 47: 3524-3529. 536

79. SOLOMAKOS Ν, GOVARIS Α, ANGELIDIS AS, POURNARAS S, ROTHI BURRIEL A, KRITAS SK AND 537

PAPAGEORGIOU DK. Occurrence, virulence genes and antibiotic resistance of Escherichia coli 538

O157 isolated from raw bovine, caprine and ovine milk in Greece. Food Microbiology 2009; 26: 539

865-871. 540

80. IKONOMIDIS A, NEOU E, GOGOU V, VRIONI G, TSAKRIS A, POURNARAS S. Heteroresistance 541

to meropenem in carbapenem-susceptible Acinetobacter baumannii. Journal of Clinical 542

Microbiology 2009; 47: 4055-4059. 543

81. IKONOMIDIS A, VASDEKI A, KRISTO I, MANIATIS AN, TSAKRIS A, MALIZOS KN, POURNARAS 544

S. Association of biofilm formation and methicillin-resistance with accessory gene regulator 545

(agr) loci in Greek Staphylococcus aureus clones. Microbial Pathogenesis 2009; 47: 341-344. 546

82. PAPAIOANNOU AI, KOUTSOKERA A, TANOU K, KIROPOULOS TS, TSILIONI I, OIKONOMIDI S, 547

LIADAKI K, POURNARAS S, GOURGOULIANIS KI, KOSTIKAS K. The acute effect of smoking in 548

healthy and asthmatic smokers. European Journal of Clinical Investigation 2009; 40:103-109. 549

83. DAFOPOULOS K, CHALVATZAS N, KOSMAS G, KALLITSARIS A, POURNARAS S, MESSINIS IE . 550

The effect of estrogens on plasma ghrelin concentrations in women. Journal of Endocrinological 551

Investigation 2010; 33: 109-112. 552

84. MIRIAGOU V, CORNAGLIA G, EDELSTEIN M, GALANI I, GISKE CG, GNIADKOWSKI M, 553

MALAMOU-LADA E, MARTINEZ-MARTINEZ L, NAVARRO F, NORDMANN P, PEIXE L, POURNARAS 554

S, ROSSOLINI GM, TSAKRIS A, VATOPOULOS A, CANTÓN R. Acquired carbapenemases in Gram-555

negative bacterial pathogens: detection and surveillance issues. Clinical Microbiology and 556

Infection 2010; 16: 112-122. 557

85. MELETIADIS J, POURNARAS S, ROILIDES E, WALSH TJ. Defining Fractional Inhibitory 558

Concentration Index Cutoffs for additive Interactions based on Self-Drug Additive Combinations, 559

Monte Carlo Simulation Analysis and in vitro-in vivo Correlation Data for Antifungal Drug 560

Combinations against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy 2010; 561

54: 602-609. 562

86. GIANNOULI S, LABROU M, KYRITSIS A, IKONOMIDIS A, POURNARAS S, STATHOPOULOS C, 563

TSAKRIS A. Detection of mutations in the FemXAB protein family in oxacillin-susceptible mecA-564

positive Staphylococcus aureus clinical isolates. Journal of Antimicrobial Chemotherapy 2010; 565

65: 626-633. 566

87. POURNARAS S, POULOU A, TSAKRIS A. Inhibitor-based methods for the detection of KPC 567

carbapenemase-producing Enterobacteriaceae in clinical practice by using boronic acid 568

compounds. Journal of Antimicrobial Chemotherapy 2010, 65: 1319-1321, Leading article. 569

18

88. ZARKOTOU O, POURNARAS S, VOULGARI E, CHRYSOS G, PREKATES A, VOUTSINAS D, 570

THEMELI-DIGALAKI K, TSAKRIS A. Risk factors and outcomes associated with acquisition of 571

colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control Study. 572

Journal of Clinical Microbiology 2010; 48: 2271-2274. 573

89. POURNARAS S, POULOU A, VOULGARI E, VRIONI G, KRISTO I, TSAKRIS A. Detection of the 574

new metallo-{beta}-lactamase VIM-19 along with KPC-2, CMY-2 and CTX-M-15 in Klebsiella 575

pneumoniae. Journal of Antimicrobial Chemotherapy 2010, 65: 1604-1607. 576

90. TSAKRIS A, POULOU A, POURNARAS S, VOULGARI E, VRIONI G, THEMELI-DIGALAKI K, 577

PETROPOULOU D, SOFIANOU D. A simple phenotypic method for the differentiation of metallo-578

β-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. Journal 579

of Antimicrobial Chemotherapy 2010, 65: 1664-1671. 580

91. PROTONOTARIOU E, DIMITROULIA E, POURNARAS S, PITIRIGA V, SOFIANOU D, TSAKRIS A. 581

Trends in antimicrobial resistance of clinical isolates of Enterococcus faecalis and Enterococcus 582

faecium in Greece between 2002 and 2007. Journal of Hospital Infection 2010, 75: 225-227. 583

92. POURNARAS S, KRISTO I, VRIONI G, IKONOMIDIS A, POULOU A, PETROPOULOU D, TSAKRIS 584

A. Characteristics of meropenem heteroresistance in KPC carbapenemase-producing Klebsiella 585

pneumoniae. Journal of Clinical Microbiology 2010; 48: 2601-2604. 586

93. TSAKRIS A, VOULGARI E, POULOU A, KIMOULI M, POURNARAS S, RANELLOU K, 587

KOSMOPOULOU O, PETROPOULOU D. In vivo acquisition of a plasmid-mediated blaKPC-2 gene 588

among clonal isolates of Serratia marcescens. Journal of Clinical Microbiology 2010; 48: 2546-589

2549. 590

94. ANIFANDIS GM, DAFOPOULOS K, MESSINI CI, CHALVATZAS N, LIAKOS N, POURNARAS S, 591

MESSINIS IE. Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in the IVF 592

outcome. Reproductive Biology and Endocrinology 2010; 8: 91. 593

95. COSTA SS, NTOKOU E, MARTINS A, VIVEIROS M, POURNARAS S, COUTO I, AMARAL L. 594

Identification of the plasmid-encoded qacA efflux pump gene in meticillin-resistant 595

Staphylococcus aureus (MRSA) strain HPV107, a representative of the MRSA Iberian clone. 596

International Journal of Antimicrobial Agents 2010; 36:557-561. 597

96. POULOU A, SPANAKIS N, POURNARAS S, PITIRIGA V, RANELLOU K, MARKOU F, TSAKRIS A. 598

Recurrent healthcare-associated community-onset infections due to Klebsiella pneumoniae 599

producing VIM-1 metallo-{beta}-lactamase. Journal of Antimicrobial Chemotherapy 2010; 600

65:2538-2542. 601

97. KATOPODIS GD, GRIVEA IN, TSANTSARIDOU AJ, POURNARAS S, PETINAKI E, 602

SYROGIANNOPOULOS GA. Fusidic acid and clindamycin resistance in community-associated, 603

methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC 604

Infectious Diseases 2010; 10: 351. 605

98. POURNARAS S, VRIONI G, NEOU E, DENDRINOS J, DIMITROULIA E, POULOU A, TSAKRIS A. 606

Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella 607

pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assay. 608

International Journal of Antimicrobial Agents 2011; 37: 244-247. 609

99. DAFOPOULOS K, VENETIS C, MESSINI CI, POURNARAS S, ANIFANDIS G, GARAS A, MESSINIS 610

IE. Inhibin secretion in women with the polycystic ovary syndrome before and after treatment 611

with progesterone. Reproductive Biology and Endocrinology 2011; 9: 59. 612

19

100. GOVARIS A, ANGELIDIS AS, KATSOULIS K, POURNARAS S. Occurrence, virulence genes and 613

antimicrobial resistance of Escherichia coli O157 in bovine, caprine, ovine and porcine carcasses 614

in Greece. Journal of Food Safety 2011; 31: 242-249. 615

101. TSAKRIS A, POULOU A, MARKOU F, PITIRIGA V, PIPERAKI ET, KRISTO I, POURNARAS S. 616

Dissemination of Clinical Isolates of Klebsiella oxytoca Harboring CMY-31, VIM-1 and a New 617

OXY-2 Type Variant in the Community. Antimicrobial Agents and Chemotherapy 2011; 55: 618

3164-3168. 619

102. TSAKRIS A, THEMELI-DIGALAKI K, POULOU A, VRIONI G, VOULGARI E, KOUMAKI V, AGODI 620

A, POURNARAS S, SOFIANOU D. Comparative Evaluation of Combined-Disk Tests Using Different 621

Boronic Acid Compounds for Detection of Klebsiella pneumoniae Carbapenemase-Producing 622

Enterobacteriaceae Clinical Isolates. Journal of Clinical Microbiology 2011: 49:2804-9. 623

103. DAPONTE A, POURNARAS S, POLYZOS NP, TSEZOU A, SKENTOU H, ANASTASIADOU F, 624

LIALIOS G, MESSINIS IE. Soluble fms-like tyrosine kinase-1 (sFlt-1) and serum placental growth 625

factor (PlGF) as biomarkers for ectopic pregnancy and missed abortion. Journal of Clinical 626

Endocrinology and Metabolism 2011; 96: E1444-E1451. 627

104. MINAS M, KOSTIKAS K, PAPAIOANNOU AI, MYSTRIDOU P, KARETSI E, GEORGOULIAS P, 628

LIAKOS N, POURNARAS S, GOURGOULIANIS KI. The association of metabolic syndrome with 629

adipose tissue hormones and insulin resistance in patients with COPD without Co-morbidities. 630

Journal of Chronic Obstructive Pulmonary Disease 2011; 8: 414-420: 631

105. TRIKALIOTIS C, GOGOU V, POURNARAS S, TSORLINI H, KATSIFA H, RAMANTANI E, 632

ARVANITIDOU M. Identification of multi-resistant strains of Acinetobacter baumannii from an 633

ICU in Greece using sequence-based typing and PFGE. Annals of Microbiology 2011; 61: 871-634

877. 635

106. ZARKOTOU O, POURNARAS S, TSELIOTI P, DRAGOUMANOS V, RANELLOU K, PREKATES A, 636

THEMELI-DIGALAKI K, TSAKRIS A. Predictors of Mortality in Patients with Bloodstream Infections 637

Caused by KPC-Producing Klebsiella pneumoniae and Impact of Appropriate Antimicrobial 638

Treatment. Clinical Microbiology and Infection 2011; 17: 1798-1803. 639

107. GOGOU V, POURNARAS S, GIANNOULI M., VOULGARI E., PIPERAKI E.-T, ZARRILLI R, TSAKRIS 640

A. Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: A 10 year study in 641

Greece (2000-09). Journal of Antimicrobial Chemotherapy 2011; 66: 2767-2772. 642

108. IOSIFIDIS E, FARMAKI E, NEDELKOPOULOU N, TSIVITANIDOU M, KAPERONI M, 643

PENTSOGLOU V, POURNARAS S, ATHANASIOU-METAXA M, ROILIDES E. Outbreak of 644

bloodstream infections because of Serratia marcescens in a pediatric department. American 645

Journal of Infection Control 40 : 11-15: 2012. 646

109. DAPONTE A, POURNARAS S, DELIGEOROGLOU E, SKENTOU H, MESSINIS IE. Serum 647

interleukin-1β, interleukin-8 and anti-heat shock 60 Chlamydia trachomatis antibodies as 648

markers of ectopic pregnancy. J Reprod Immunol 2012; 93: 102-108. 649

110. LABROU M, MICHAIL G, NTOKOU E, PITTARAS TE, POURNARAS S, TSAKRIS A. Activity of 650

Oxacillin versus that of Vancomycin against Oxacillin-Susceptible mecA-Positive Staphylococcus 651

aureus Clinical Isolates by Population Analyses, Time-Kill Assays and a Murine Thigh Infection 652

Model. Antimicrob Agents Chemotherapy 2012; 56: 3388-3391. 653

111. TSIKRIKONIS G, MANIATIS AN, LABROU M, NTOKOU E, MICHAIL G, DAPONTE A, 654

STATHOPOULOS C, TSAKRIS A, POURNARAS S. Differences in biofilm formation and virulence 655

20

factors between clinical and fecal enterococcal isolates of human and animal origin. Microbial 656

Pathogenesis 2012; 52: 336-343. 657

112. MARAGOZIDIS P, KARANGELI M, LABROU M, DIMOULOU G, PAPASPYROU K, SALATAJ E, 658

POURNARAS S, MATSOUKA P, GOURGOULIANIS KI, BALATSOS NA. Alterations of Deadenylase 659

Expression in Acute Leukemias: Evidence for Poly(A)-Specific Ribonuclease as a Potential 660

Biomarker. Acta Haematologica 2012; 128: 39-46. 661

113. ELEFTHERIADIS, T., PISSAS, G., KARIOTI, A., ANTONIADI, G., LIAKOPOULOS, V., 662

DAFOPOULOU, K., POURNARAS S, KOUKOULIS G, STEFANIDIS, I. The Indoleamine 2,3-663

dioxygenase Inhibitor 1-methyl-tryptophan suppresses mitochondrial function, induces aerobic 664

glycolysis and decreases interleukin-10 production in human lymphocytes. Immunological 665

Investigations 2012; 41 :507-20. 666

114. TZAVARAS I, SIARKOU VI, ZDRAGAS A, KOTZAMANIDIS C, VAFEAS G , BOURTZI-667

HATZOPOULOU E, POURNARAS S, SOFIANOU D. Diversity of vanA-type vancomycin-resistant 668

Enterococcus faecium isolated from broilers, poultry slaughterers and hospitalized humans in 669

Greece. Journal of Antimicrobial Chemotherapy 2012; 67: 1811-1818. 670

115. NTOKOU E, STATHOPOULOS C, KRISTO I, DIMITROULIA E., LABROU M, VASDEKI A, MAKRIS 671

D, ZAKYNTHINOS E, TSAKRIS A, POURNARAS S. Intensive care unit dissemination of multiple 672

clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium. Journal of 673

Antimicrobial Chemotherapy 2012; 67: 1819-1823. 674

116. IOSIFIDIS E, KARAKOULA K, PROTONOTARIOU E, KAPERONI M, MATAPA E, POURNARAS S, 675

KOLIOUSKAS D, SOFIANOU D, ROILIDES E. Polyclonal Outbreak of Vancomycin-resistant 676

Enterococcus faecium in a Pediatric Oncology Department. Journal of Pediatric Hematology 677

and Oncology 2012; 34: 511-6. 678

117. ZARKOTOU O, POURNARAS S, ALTOUVAS G, PITIRIGA V, TZIRAKI M, MAMALI V, THEMELI-679

DIGALAKI K, TSAKRIS A. Comparative evaluation of tigecycline susceptibility testing methods for 680

expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens. 681

Journal of Clinical Microbiology 2012; 50: 3747-50. 682

118. POURNARAS S, NTOKOU E, ZARKOTOU O, RANELLOU K, THEMELI-DIGALAKI K, 683

STATHOPOULOS C, AND TSAKRIS A. Linezolid dependence in Staphylococcus epidermidis 684

Bloodstream Isolates. Emerging Infectious Diseases 2013; 19: 129-132. 685

119. ZARRILLI R, POURNARAS S, GIANNOULI M, TSAKRIS A. Global evolution of multidrug-686

resistant Acinetobacter baumannii clonal lineages. International Journal of Antimicrobial 687

Agents 2013; 41: 11-19. Review Article. 688

120. DAPONTE Α, DELIGEOROGLOU Ε, POURNARAS S, TSEZOU A, GARAS A, ANASTASIADOU F, 689

HADJICHRISTODOULOU C, MESSINIS IE. Angiopoietin-1 and Angiopoietin-2 as serum biomarkers 690

for ectopic pregnancy and missed abortion. A case-control study. Clinica Chimica Acta 2013; 691

415: 145-151. 692

121. MINAS M, MYSTRIDOU P, GEORGOULIAS P, POURNARAS S, KOSTIKAS K, GOURGOULIANIS 693

KI. Fetuin-A is associated with disease severity and exacerbation frequency in patients with 694

COPD. COPD. 2013; 10: 28-34. 695

122. DAPONTE A, DELIGEOROGLOU E, POURNARAS S, HADJICHRISTODOULOU C, GARAS A, 696

ANASTASIADOU F, MESSINIS IE. Interleukin-15 (IL-15) and anti-C1q antibodies as serum 697

biomarkers for ectopic pregnancy and missed abortion. Clinical and Developmental Immunol. 698

2013; 2013: 637513. 699

21

123. KRISTO I, PITIRIGA V, POULOU A, ZARKOTOU O, KIMOULI M, POURNARAS S, TSAKRIS A. 700

Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae 701

harbouring extended-spectrum beta-lactamases using the updated Clinical and Laboratory 702

Standards Institute interpretive criteria. International Journal of Antimicrobial Agents 2013; 703

41: 383-387. 704

124. PINAKA O, POURNARAS S, MOUCHTOURI V, PLAKOKEFALOS E, KATSIAFLAKA A, 705

KOLOKYTHOPOULOU F, BARBOUTSI E, BITSOLAS N, HADJICHRISTODOULOU C. Shiga toxin-706

producing Escherichia coli in Central Greece: prevalence and virulence genes of O157:H7 and 707

non-O157 in animal feces, vegetables, and humans. European Journal of Clinical Microbiology 708

& Infectious Diseases 2013; 32: 1401-1408. 709

125. POURNARAS S, KOCK R, MOSSIALOS D, MELLMANN A, SAKELLARIS V, STATHOPOULOS C, 710

FRIEDRICH AW, TSAKRIS A. Detection of a phylogenetically distinct IMP-type metallo-711

blactamase, IMP-35, in a CC235 Pseudomonas aeruginosa from the Dutch–German border 712

region (Euregio). Journal of Antimicrobial Chemotherapy 2013; 68: 1271-1276. 713

126. POURNARAS S, ZARKOTOU O, POULOU A, KRISTO I, VRIONI G, THEMELI-DIGALAKI K, 714

TSAKRIS A. A combined disk test for direct differentiation of carbapenemase-producing 715

enterobacteriaceae in surveillance rectal swabs. Journal of Clinical Microbiology 2013; 51: 716

2986-2990. 717

127. IOSIFIDIS E, EVDORIDOU I, AGAKIDOU E, CHOCHLIOUROU E, PROTONOTARIOU E, 718

KARAKOULA K, STATHIS I, SOFIANOU D, DROSSOU-AGAKIDOU V, POURNARAS S, ROILIDES E. 719

Vancomycin-resistant Enterococcus outbreak in a neonatal intensive care unit: epidemiology, 720

molecular analysis and risk factors. American Journal of Infection Control 2013; 41: 857-861. 721

128. POURNARAS S, STATHOPOULOS C, TSAKRIS A. Oxacillin-susceptible MRSA: could it become 722

a successful MRSA type? Future Microbiology 2013; 8: 1365-1367. 723

129. KERASIOTI E, STAGOS D, JAMURTAS A, KISKINI A, KOUTEDAKIS Y, GOUTZOURELAS N, 724

POURNARAS S, TSATSAKIS AM, KOURETAS D. Anti-inflammatory effects of a special 725

carbohydrate-whey protein cake after exhaustive cycling in humans. Food and Chemical 726

Toxicology 2013; 61: 42-46. 727

130. MICHAIL G, LABROU M, PITIRIGA V, MANOUSAKA S, SAKELLARIDIS N, TSAKRIS A, 728

POURNARAS S. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or 729

Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. 730

Antimicrobial Agents and Chemotherapy 2013; 57: 6028-6033. 731

131. STEFANIDIS I, VAINAS A, DARDIOTIS E, GIANNAKI CD, GOURLI P, PAPADOPOULOU D, 732

VAKIANIS P, PATSIDIS E, ELEFTHERIADIS T, LIAKOPOULOS V, POURNARAS S, SAKKAS GK, 733

ZINTZARAS E, HADJIGEORGIOU GM. Restless legs syndrome in hemodialysis patients: an 734

epidemiologic survey in Greece. Sleep Medicine 2013; 14: 1381-1386. 735

132. DAPONTE A, DELIGEOROGLOU E, GARAS A, POURNARAS S, HADJICHRISTODOULOU C, 736

MESSINIS IE. Activin A and follistatin as biomarkers for ectopic pregnancy and missed abortion. 737

Disease Markers 2013; 35: 497-503. 738

133. DAPONTE A, POURNARAS S, TSAKRIS A. Self-sampling for high-risk human papillomavirus 739

detection: future cervical cancer screening? Womens’ Health (Lond Engl) 2014; 10: 115-8. 740

134. NEOU E, MICHAIL G, TSAKRIS A, POURNARAS S. Virulence of Acinetobacter baumannii 741

Exhibiting Phenotypic Heterogeneous Growth against Meropenem in a Murine Thigh Infection 742

Model. Antibiotics 2013; 2: 73-82. 743

22

135. MANTZANA P, POURNARAS S, SKENTOU C, DELIGEOROGLOU E, KATSIOULIS A, 744

ANTONAKOPOULOS G, HADJICHRISTODOULOU C, TSAKRIS A, MESSINIS IE, DAPONTE A. 745

Applicability of self-obtained urine and vaginal samples for HPV-16, -18, -31 and -45 cervical 746

cancer screening in pregnancy: a pilot cross-sectional study. Future Virology 2014; 9:385-395. 747

136. POURNARAS S, GOGOU V, GIANNOULI M, DIMITROULIA E, DAFOPOULOU K, TSAKRIS A, 748

ZARRILLI R. Single locus sequence-based typing of blaOXA-51-like gene for rapid classification of 749

Acinetobacter baumannii clinical isolates to international clones. Journal of Clinical 750

Microbiology 2014; 52: 1653-1657. 751

137. KOKKORI S, APOSTOLIDI M, TSAKRIS A, POURNARAS S, STATHOPOULOS C, DINOS G. 752

Linezolid-dependent function and structure adaptation of ribosomes in a Staphylococcus 753

epidermidis strain exhibiting linezolid dependence. Antimicrobial Agents and Chemotherapy 754

2014; 58: 4651-4656. 755

138. POULOU A, GRIVAKOU E, VRIONI G, KOUMAKI V, PITTARAS T, POURNARAS S, TSAKRIS A. 756

Modified CLSI ESBL Confirmatory Test for The Phenotypic Detection of Extended-Spectrum β-757

Lactamases among Enterobacteriaceae Producing Various β-Lactamases. Journal of Clinical 758

Microbiology 2014; 52: 1483-1489. 759

139. POURNARAS S, POULOU A, DAFOPOULOU K, NAIT CHABANE Y, KRISTO I, MAKRIS D, 760

HARDOUIN J, COSETTE P, TSAKRIS A, DÉ E. Growth Retardation, Reduced Invasiveness and 761

Impaired Colistin-Mediated Cell Death Associated with Colistin Resistance Development in 762

Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 2014; 58: 828-832. 763

140. MELETIS G, VAVATSI N, EXINDARI M, PROTONOTARIOU E, SIANOU E, HAITOGLOU C, 764

SOFIANOU D, POURNARAS S, DIZA E. Accumulation of carbapenem resistance mechanisms in 765

VIM-2-producing Pseudomonas aeruginosa under selective pressure. European Journal of 766

Clinical Microbiology and Infectios Diseases 2014; 33: 253-258. 767

141. TRATSELAS A, SIMITSOPOULOU M, GIANNAKOPOULOU A, DORI I, SAOULIDIS S, KOLLIOS K, 768

PAPAIOANNIDOU P, POURNARAS S, ROILIDES E. Outcome of murine pyelonephritis caused by 769

extended spectrum β-lactamase-producing Esherichia coli: effect of ceftriaxone. Antimicrobial 770

Agents and Chemotherapy 2014; 58: 7102-7111. 771

142. VRIONI G, BOURDAKIS A, PAPPAS G, PITIRIGA V, MAVROULI M, POURNARAS S, TSAKRIS A. 772

Administration of a Triple vs. Standard Double Antimicrobial Regimen to Human Brucellosis 773

Efficiently Eliminates Bacterial DNA Load. Antimicrobial Agents and Chemotherapy 2014; 58: 774

7541-7544. 775

143. MELLOU K, KATSIOULIS A, POTAMITI-KOMI M, POURNARAS S, KYRITSI M, KATSIAFLAKA A, 776

KALLIMANI A, KOKKINOS P, PETINAKI E, SIDEROGLOU T, GEORGAKOPOULOU T, VANTARAKIS A, 777

HADJICHRISTODOULOU C. A large waterborne gastroenteritis outbreak in central Greece, March 778

2012: challenges for the investigation and management. Epidemiology and Infection 2014; 142: 779

40-50. 780

144. DIMOULIS A, PASTAKA C, TSOLAKI V, TSILIONI I, POURNARAS S, LIAKOS N, GEORGOULIAS P, 781

GOURGOULIANIS K. Model assessment (HOMA) index in stable chronic obstructive pulmonary 782

disease (COPD) patients with chronic hypercapnic respiratory failure: a pilot study. COPD 2015; 783

12: 427-34. 784

145. TSAKRIS A, POULOU A, BOGAERTS P, DIMITROULIA E, POURNARAS S, GLUPCZYNSKI Y. 785

Evaluation of a new phenotypic OXA-48 disk test for differentiation of OXA-48 carbapenemase-786

23

producing Enterobacteriaceae clinical isolates. Journal of Clinical Microbiology 2015; 53: 1245-787

1251. 788

146. KARAVASILIS V, ZARKOTOU O, PANOPOULOU M, KACHRIMANIDOU M, THEMELI-DIGALAKI 789

K, STYLIANAKIS A, GENNIMATA V, NTOKOU E, STATHOPOULOS C, TSAKRIS A, POURNARAS S; 790

GREEK STUDY GROUP ON STAPHYLOCOCCAL LINEZOLID RESISTANCE. Wide dissemination of 791

linezolid-resistant Staphylococcus epidermidis in Greece is associated with a linezolid-dependent 792

ST22 clone. Journal of Antimicrobial Chemotherapy 2015; 70: 1625-1629. 793

147. POURNARAS S, SABAT AJ, GRUNDMANN H, HENDRIX R, TSAKRIS A, FRIEDRICH AW. Driving 794

forces of mechanisms regulating oxacillin-resistance phenotypes of MRSA: truly oxacillin-795

susceptible mecA-positive Staphylococcus aureus clinical isolates also exist. Current 796

Pharmaceutical Design 2015; 21: 2048-2053. 797

148. DAFOPOULOU K, ZARKOTOU O, DIMITROULIA E, HADJICHRISTODOULOU C, GENNIMATA V, 798

POURNARAS S, TSAKRIS A. Comparative evaluation of colistin susceptibility testing methods 799

among carbapenem-non-susceptible Klebsiella pneumoniae and Acinetobacter baumannii 800

clinical isolates. Antimicrobial Agents and Chemotherapy 2015; 59: 4625-30. 801

149. SABAT A, POURNARAS S, AKKERBOOM V, TSAKRIS A, GRUNDMANN H, FRIEDRICH A. 802

Whole-genome analysis of an oxacillin-susceptible CC80 mecA-positive Staphylococcus aureus 803

clinical isolate: Insights into the mechanisms of cryptic methicillin resistance. Journal of 804

Antimicrobial Chemotherapy 2015; 70: 2956-64. 805

150. APOSTOLIDI M, SAAD NY, DRAINAS D, POURNARAS S, BECKER HD, STATHOPOULOS C. A 806

glyS T-box riboswitch with species-specific structural features responding to both proteinogenic 807

and nonproteinogenic tRNAGly isoacceptors. RNA 2015; 21: 1790-806. 808

151. SAHL JW, DEL FRANCO M, POURNARAS S, COLMAN RE, KARAH N, DIJKSHOORN L, ZARRILLI 809

R. Phylogenetic and genomic diversity in isolates from the globally distributed Acinetobacter 810

baumannii ST25 lineage. Sci Rep. 2015; 5: 15188. 811

152. POURNARAS S, KOUMAKI V, GENNIMATA V, KOUSKOUNI E, TSAKRIS A. In Vitro Activity of 812

Tigecycline Against Acinetobacter baumannii: Global Epidemiology and Resistance Mechanisms. 813

Adv Exp Med Biol. 2016; 897: 1-14. 814

153. HADJICHRISTODOULOU C, POURNARAS S, MAVROULI M, MARKA A, TSERKEZOU P, BAKA A, 815

BILLINIS C, KATSIOULIS A, PSAROULAKI A, PAPA A, PAPADOPOULOS N, MAMURIS Z, TSAKRIS A, 816

KREMASTINOU J; MALWEST Project. West Nile Virus Seroprevalence in the Greek Population in 817

2013: A Nationwide Cross-Sectional Survey. PLoS One 2015; 10: e0143803. 818

154. DAFOPOULOU K, XAVIER BB, HOTTERBEEKX A, JANSSENS L, LAMMENS C, DÉ E, GOOSSENS 819

H, TSAKRIS A, MALHOTRA-KUMAR S, POURNARAS S. Colistin-Resistant Acinetobacter baumannii 820

Clinical Strains with Deficient Biofilm Formation. Antimicrob Agents Chemother. 2015; 60: 821

1892-5. 822

155. VOULGARI E, POULOU A, DIMITROULIA E, POLITI L, RANELLOU K, GENNIMATA V, MARKOU 823

F, POURNARAS S, TSAKRIS A. Emergence of OXA-162 Carbapenemase- and DHA-1 AmpC 824

Cephalosporinase-Producing Sequence Type 11 Klebsiella pneumoniae Causing Community-825

Onset Infection in Greece. Antimicrob Agents Chemother. 2015; 60: 1862-4. 826

156. GUTIÉRREZ-GUTIÉRREZ B, BONOMO RA, CARMELI Y, PATERSON DL, ALMIRANTE B, 827

MARTÍNEZ-MARTÍNEZ L, OLIVER A, CALBO E, PEÑA C, AKOVA M, PITOUT J, ORIGÜEN J, PINTADO 828

V, GARCÍA-VÁZQUEZ E, GASCH O, HAMPRECHT A, PRIM N, TUMBARELLO M, BOU G, VIALE P, 829

TACCONELLI E, ALMELA M, PÉREZ F, GIAMARELLOU H, CISNEROS JM, SCHWABER MJ, VENDITTI 830

24

M, LOWMAN W, BERMEJO J, HSUEH PR, MORA-RILLO M, GRACIA-AHULFINGER I, PASCUAL A, 831

RODRÍGUEZ-BAÑO J; REIPI/ESGBIS/INCREMENT Group. Ertapenem for the treatment of 832

bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-833

registered cohort study. J Antimicrob Chemother. 2016 Feb 22. pii: dkv502. [Epub ahead of 834

print]. 835

157. PAPAGIANNIS D, TSIMTSIOU Z, CHATZICHRISTODOULOU I, ADAMOPOULOU M, 836

KALLISTRATOS I, POURNARAS S, ARVANITIDOU M, RACHIOTIS G. Hepatitis B Virus Vaccination 837

Coverage in Medical, Nursing, and Paramedical Students: A Cross-Sectional, Multi-Centered 838

Study in Greece. Int J Environ Res Public Health 2016 Mar 15;13(3). pii: E323. 839

840

841

842